Literature DB >> 11275363

Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition.

G C Das1, D Holiday, R Gallardo, C Haas.   

Abstract

The effective dose, schedule, molecular basis of the cytotoxicity of taxol and their dependence on the genetic background in tumor cells are still not well understood. Here, we examined how the dose-response relationship for taxol varies in lung cancer cells with different p53 status and under isogenic conditions. DNA content analyses in A 549 (p53, +/+) and H 1299 (p53, -/-) cells, showed that taxol progressively induced G2/M arrest in both cell lines in a concentration-dependent manner, which was accompanied by a parallel decrease in the G1 population. G2/M arrest, however, occurred at a lower concentration in A 549 cell lines than in H 1299 cells. The S-phase population in A 549 cells was not significantly changed up to 0.025 microM, but dropped by six-fold at 1.0 microM taxol, in contrast to that in H 1299 cells. A sub-G1 apoptotic population was present at 24 h, even at 0.002 microM taxol, when G2/M arrest was not appreciably detected. In both cell lines, the maximum apoptosis of about 28% was achieved at 0.025 microM taxol, implicating that wild-type p53 does not modulate the level of taxol-induced apoptosis. When we examined the role of the wild-type p53 in isogenic cell lines developed in a H 1299 background, the maximum level of apoptosis was in the range of 28-34% at a drug concentration around 0.03 microM, not significantly different from that observed in parental H 1299 cells. We conclude that taxol is effective in inducing apoptosis at very low doses (0.020-0.035 microM), and that the presence or absence of the wild-type p53 does not make a statistically significant difference in the level of apoptotic cell death in these lung cancer cell lines, but the maximum is attained at a lower drug concentration in the presence of p53.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11275363     DOI: 10.1016/s0304-3835(01)00404-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  32 in total

1.  A high throughput drug screen based on fluorescence resonance energy transfer (FRET) for anticancer activity of compounds from herbal medicine.

Authors:  H Tian; L Ip; H Luo; D C Chang; K Q Luo
Journal:  Br J Pharmacol       Date:  2007-01-18       Impact factor: 8.739

2.  Mechanism of action of the anti-inflammatory connexin43 mimetic peptide JM2.

Authors:  J Matthew Rhett; Bennett W Calder; Stephen A Fann; Heather Bainbridge; Robert G Gourdie; Michael J Yost
Journal:  Am J Physiol Cell Physiol       Date:  2017-07-12       Impact factor: 4.249

3.  Combination therapy induces unfolded protein response and cytoskeletal rearrangement leading to mitochondrial apoptosis in prostate cancer.

Authors:  Sandeep Kumar; Ajay K Chaudhary; Rahul Kumar; Jordan O'Malley; Anna Dubrovska; Xinjiang Wang; Neelu Yadav; David W Goodrich; Dhyan Chandra
Journal:  Mol Oncol       Date:  2016-03-31       Impact factor: 6.603

4.  A highly tumor-targeted nanoparticle of podophyllotoxin penetrated tumor core and regressed multidrug resistant tumors.

Authors:  Aniruddha Roy; Mark J Ernsting; Elijus Undzys; Shyh-Dar Li
Journal:  Biomaterials       Date:  2015-03-03       Impact factor: 12.479

5.  Lead optimization of dual tubulin and Hsp27 inhibitors.

Authors:  Bo Zhong; Rati Lama; Daniel G Kulman; Bibo Li; Bin Su
Journal:  Eur J Med Chem       Date:  2014-04-13       Impact factor: 6.514

6.  A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.

Authors:  Yi Shi; Lin Sun; Ge Chen; Dongyan Zheng; Li Li; Wanguo Wei
Journal:  Target Oncol       Date:  2015-04-29       Impact factor: 4.493

7.  Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.

Authors:  Evan R Zynda; Vitaliy Matveev; Michael Makhanov; Alexander Chenchik; Eugene S Kandel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Activatable molecular systems using homologous near-infrared fluorescent probes for monitoring enzyme activities in vitro, in cellulo, and in vivo.

Authors:  Zongren Zhang; Jinda Fan; Philip P Cheney; Mikhail Y Berezin; W Barry Edwards; Walter J Akers; Duanwen Shen; Kexian Liang; Joseph P Culver; Samuel Achilefu
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

9.  Antitumor activity of a sulfated polysaccharide from Enteromorpha intestinalis targeted against hepatoma through mitochondrial pathway.

Authors:  Xuxia Wang; Ying Chen; Jingjie Wang; Zhenxiong Liu; Shuguang Zhao
Journal:  Tumour Biol       Date:  2013-10-02

10.  SPR064, a pro-drug of paclitaxel, has anti-tumorigenic effects in endometrial cancer cell lines and mouse models.

Authors:  Xiaoling Zhao; Weimin Kong; Katherine Tucker; Allison Staley; Yali Fan; Wenchuan Sun; Yajie Yin; Yu Huang; Ziwei Fang; Jiandong Wang; Somdutta Sen; Sundeep Dugar; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2020-08-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.